ASSOCIATION OF FAS-670 GENE POLYMORPHISM WITH RISK OF OVARIAN CANCER IN NORTH INDIAN POPULATION

Minu Keshkar, Nisha Rani Agarwal, Kiran Singh, Bharat Bhushan Khurse

Abstract


Ovarian cancer is the second most common gynaecological cancer. Apoptosis is a normal component of the development and health of
multicellular organisms. Abnormal regulation of apoptosis is probably to contribute to pathogenesis of cancer. Fas, is a transmembrane receptor
that plays a central role in apoptotic signaling. SNPs at -670 of Fas gene alters the function or structure of the encoded proteins, and is sufficient for
its decreased expression and reducing the cell apoptosis leading to malignant transformation.
METHODS: A single-nucleotide polymorphism at -670 of Fas gene promoter (A/G) was examined in a total of 75 blood samples from (25
normal healthy and 50 ovarian cancer), using PCR-RFLP technique.
RESULTS: There was no significant difference found in the genotype prevalence between control and ovarian tumor patients. The Fas -670 GG
genotype was not associated with an increased risk for the development of ovarian tumor (OR=1.0108 95% CI=0.274-3.7201) compared with the
AA genotype.


Keywords


Apoptosis, Fas, Single-nucleotide Polymorphism.

Full Text:

PDF

References


Nagata S, Golstein P. The Fas death factor. Science 1995;267:

–56.

Wajant H (2002). "The Fas signaling pathway: more than a paradigm". Science 296 (5573): 1635–6.

Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169–78.

Thompson CB, Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-1462.

Huang QR, et al Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol. Immunol. 1997;34:577-582.

Maureen A. Riopel, Amy Spellerberg, Constance A. Griffin, and Elizabeth J. Perlman2 Department of Pathology, The Johns Hopkins Hospital, Baltimore, Mary/and 21287. Genetic Analysis of Ovarian Germ Cell Tumors by Comparative Genomic Hybridization (CANCER RESEARCH 58, 3105-3110. July 15. 1998)

Kanemitsu S, Ihara K, Saifddin A et al. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 2002;29:1183–8.

Huang QR, Danis V, Lassere M, Edmonds J, Manolios N. Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatology (Oxford) 1999;38:645–51.

Lee YH, Kim YR, Ji JD, Sohn J, Song GG. Fas promoter 2670 polymorphism is associated with development of anti-RNP antibodies in systemic lupus erythematosus. J Rheumatol 2001;28: 2008–11.

Lai HC, Sytwu HK, Sun CA et al. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer 2003;103:221–5.

Tamandani, DMk; Sobti, RC; Shekari, M CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY Volume: 35 Issue: 3 Pages: 183-186.

H Das, T Koizumi, T Sugimoto, S Chakraborty, T Ichimura, K Hasegawa and R Nishimura: Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR; British Journal of Cancer (2000) 82(10), 1682–1688.

M. Ueda, Y. Terai, K. Kanda, M. Kanemura, M. Takehara, H. Yamaguchi,K. Nishiyama, M. YASUDA & M. Ueki Fas gene promoter -670 polymorphism in gynecological cancer. Int J Gynecol Cancer 2006, 16 (Suppl. 1), 179–182


Refbacks

  • There are currently no refbacks.